There has been and continues to be a surge in biotech innovation. But a pertinent question arises: how frequently are older, now outdated technologies phased out? Precision's Ross Maclean, Phil Cyr and Ray Roth discuss the reluctance to abandon practices and technologies despite the availability of newer, better alternatives, and list how biopharma can lead the way.